Dermatology

In Psoriasis and Psoriatic Arthritis, CT-P13 Is Safe and Effective 1 Year After Mandatory Switch

October 28th 2019

By Kelly Davio

Article

Researchers reported on 1-year follow-up among patients at 2 centers, all of whom had psoriasis or psoriatic arthritis, after Brazilian health authorities issued a 2017 mandate that patients being treated with the reference infliximab be switched to CT-P13, and that new starts be given the biosimilar instead of the reference.

Samsung Bioepis' Etanercept Biosimilar Performs in Real-World Treatment of Psoriasis

October 9th 2019

By Kelly Davio

Article

In treating patients with moderate to severe psoriasis, Samsung Bioepis’ etanercept biosimilar, approved in the European Union as Benepali and in the United States as Eticovo, was shown to be effective in a registry study.

Head-to-Head Study Shows Ixekizumab Outperforms Adalimumab in Psoriatic Arthritis

October 3rd 2019

By Kelly Davio

Article

Could adalimumab and its biosimilars become a less attractive option for treating some inflammatory diseases in the face of new therapeutic choices like interleukin-17 inhibitors? In the case of ixekizumab, a recent head-to-head study versus adalimumab showed that the newer product was superior in terms of improving joint and skin disease in patients with psoriatic arthritis.

Step Therapy in RA or PsA Leads to Worse Treatment Outcomes, Study Says

September 16th 2019

By Allison Inserro

Article

A recent study says step therapy in rheumatoid (RA) or psoriatic arthritis (PsA) can hurt treatment outcomes.

Therapeutic Drug Monitoring Has Promise for Improving Psoriasis Outcomes, Study Suggests

September 2nd 2019

By The Center for Biosimilars Staff

Article

There is increasing evidence to suggest that therapeutic drug monitoring (TDM) will allow for more tailored and rational use of biologics in psoriasis.

Ahead of US Biosimilar Etanercept Competition, Amgen Acquires Apremilast

August 27th 2019

By The Center for Biosimilars Staff

Article

Amgen announced yesterday that it will acquire apremilast (Otezla) from Celgene. The small-molecule drug, which inhibits phosphodiesterase 4, specific for cyclic adenosine monophosphate, is an orally administered therapy for patients with psoriatic arthritis and patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.

Celltrion to Start Phase 1 Trial of Omalizumab Biosimilar, CT-P39

July 16th 2019

By Kelly Davio

Article

Republic of Korea–based drug maker Celltrion announced this week that it is launching its first clinical trial of CT-P39, a proposed biosimilar omalizumab referencing Xolair. The company says that it plans to enter phase 3 trials in the first half of 2020 and has plans to commercialize the biosimilar by 2022.

No Difference Seen in Cardiac Effects Between Ustekinumab, Anti-TNF Drugs for Psoriasis

July 15th 2019

By The Center for Biosimilars Staff

Article

A recent study found no difference in the risk of developing atrial fibrillation (AF) or major adverse cardiovascular events (MACE) associated with ustekinumab versus anti–tumor necrosis factor (anti-TNF) therapy in patients with psoriasis or psoriatic arthritis.

As Biosimilar Adalimumab Gains Ground in Europe, Ixekizumab Shows Superiority to Humira in PsA

July 2nd 2019

By Kelly Davio

Article

Given the head-to-head data from the SPIRIT trial, Humira maker AbbVie may face even further challenges in trying to maintain its sales as newer products like ixekizumab advance in such therapeutic areas as psoriatic arthritis (PsA).

Two Studies Report on Biosimilar Rituximab's Utility in Treating Pemphigus

June 15th 2019

By The Center for Biosimilars Staff

Article

Given the cost of the brand-name drug, there is interest among providers, particularly in contexts with limited resources, in using a biosimilar rituximab to treat pemphigus, and recently, 2 studies reported on the use of biosimilar rituximab in treating this disease.